Ranbaxy Claims Greatest Indian Market Share, Ahead of Cipla, GSK
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories beat out Cipla as India's drug maker with the highest share of the domestic market in July. Ranbaxy claimed a 5.1 percent market share during the month, while Cipla recorded a 4.89 percent share. Ranbaxy's sales for the month increased by 13.4 percent compared with Cipla's 9.7 percent. The audit by ORG-IMS gave U.K. drug maker GlaxoSmithKline the third largest market share, followed by Indian makers Piramal Healthcare and Zydus Cadila. (Click here for more
You may also be interested in...
GSK To Take Second Shot At The Rural Indian Market; Considering Customized Strategy
MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.